title: Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.
abstract: In order to advance therapeutic applications of nicotinic ligands, continuing research efforts are being directed toward the identification and characterization of novel nicotinic acetylcholine receptor (nAChR) ligands that are both potent and subtype selective. Herein we report the synthesis and pharmacological evaluation of members of a new series of 3-alkoxy-5-aminopyridine derivatives that display good selectivity for the α4β2-nAChR subtype based on ligand binding and functional evaluations. The most potent ligand in this series, compound 64, showed high radioligand binding affinity and selectivity for rat α4β2-nAChR with a K(i) value of 1.2 nM and 4700-fold selectivity for α4β2- over α3β4-nAChR, and ∼100-fold selectivity for functional, high-sensitivity, human α4β2-nAChR over α3β4*-nAChR. In the mouse forced swim test, compound 64 exhibited antidepressant-like effects. Structure-activity relationship (SAR) analyses suggest that the introduction of additional substituents to the amino group present on the pyridine ring of the N-demethylated analogue of compound 17 can provide potent α4β2-nAChR-selective ligands for possible use in treatment of neurological and psychiatric disorders including depression.
authors.affiliation: Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, USA.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Liu
authors.forename: J Brek
authors.initials: JB
authors.lastname: Eaton
authors.forename: Barbara
authors.initials: B
authors.lastname: Caldarone
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Lukas
authors.forename: Alan P
authors.initials: AP
authors.lastname: Kozikowski
mesh_terms: D000631:Aminopyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001384:Azetidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001667:Binding, Competitive; D002460:Cell Line; D002522:Chlorocebus aethiops; D006224:Cricetinae; D003412:Cricetulus; D054333:Drug Partial Agonism; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016548:Prosencephalon / Q000378:metabolism; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011759:Pyrrolidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D011978:Receptors, Nicotinic / Q000502:physiology*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: C553280:3-((2-pyrrolidinyl)methoxy)-5-phenylaminopyridine; D000631:Aminopyridines; D000928:Antidepressive Agents; D001384:Azetidines; D008024:Ligands; D011725:Pyridines; D011759:Pyrrolidines; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2; C514816:sazetidine-A
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):732-43
references.pmid: 19523455
references.citation: Handb Clin Neurol. 2008;89:273-90
references.pmid: 18631752
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):723-30
references.pmid: 15276699
references.citation: CNS Drug Rev. 2004 Summer;10(2):167-82
references.pmid: 15179445
references.citation: Physiol Behav. 2008 Oct 20;95(3):408-12
references.pmid: 18671990
references.citation: Drug Discov Today. 2005 Dec;10(23-24):1657-65
references.pmid: 16376826
references.citation: J Neurochem. 1999 Mar;72(3):1117-24
references.pmid: 10037483
references.citation: J Neurosci Res. 1996 Apr 15;44(2):97-105
references.pmid: 8723217
references.citation: Biochem Pharmacol. 2008 Nov 15;76(10):1175-83
references.pmid: 18691557
references.citation: J Med Chem. 2009 Jul 23;52(14):4126-41
references.pmid: 19552432
references.citation: Biochemistry. 1987 May 19;26(10):2807-14
references.pmid: 3038165
references.citation: Mol Cell Neurosci. 1993 Feb;4(1):1-12
references.pmid: 19912902
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1212-23
references.pmid: 17689498
references.citation: J Biol Chem. 1980 Jun 25;255(12):5578-85
references.pmid: 7380828
references.citation: Neuropharmacology. 1996 Jun;35(6):725-34
references.pmid: 8887981
references.citation: J Pharmacol Exp Ther. 2000 Feb;292(2):461-7
references.pmid: 10640281
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1224-34
references.pmid: 17631864
references.citation: Mol Pharmacol. 2004 Sep;66(3):675-82
references.pmid: 15322260
references.citation: Mol Pharmacol. 2006 Oct;70(4):1454-60
references.pmid: 16857741
references.citation: Bioorg Med Chem Lett. 1998 Oct 6;8(19):2797-802
references.pmid: 9873625
references.citation: J Med Chem. 1996 Aug 16;39(17):3235-7
references.pmid: 8765504
references.citation: J Psychiatr Res. 2006 Aug;40(5):404-18
references.pmid: 15979645
references.citation: J Pharmacol Exp Ther. 1997 Jan;280(1):346-56
references.pmid: 8996215
references.citation: Trends Pharmacol Sci. 2008 Mar;29(3):151-8
references.pmid: 18262664
references.citation: J Med Chem. 2005 Jul 28;48(15):4705-45
references.pmid: 16033252
references.citation: J Med Chem. 2010 Mar 11;53(5):2204-14
references.pmid: 20158204
references.citation: CNS Drug Rev. 2004 Summer;10(2):147-66
references.pmid: 15179444
references.citation: J Pharmacol Exp Ther. 1996 Dec;279(3):1413-21
references.pmid: 8968366
references.citation: ChemMedChem. 2007 Jun;2(6):746-67
references.pmid: 17295372
references.citation: Bioorg Med Chem. 2005 Feb 1;13(3):799-807
references.pmid: 15653347
references.citation: J Pharmacol Exp Ther. 1996 Dec;279(3):1422-9
references.pmid: 8968367
references.citation: Biochem Pharmacol. 1999 Sep 15;58(6):917-23
references.pmid: 10509744
references.citation: Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36
references.pmid: 596982
references.citation: Bioorg Med Chem Lett. 1998 Feb 3;8(3):249-54
references.pmid: 9871663
references.citation: Angew Chem Int Ed Engl. 2008;47(34):6338-61
references.pmid: 18663711
references.citation: Pharmacol Rev. 2009 Mar;61(1):39-61
references.pmid: 19293145
references.citation: Drug Discov Today. 2006 Feb;11(3-4):165-74
references.pmid: 16533715
references.citation: Int Rev Neurobiol. 2007;78:225-46
references.pmid: 17349863
references.citation: ChemMedChem. 2009 Aug;4(8):1279-91
references.pmid: 19569163
references.citation: J Pharmacol Exp Ther. 1999 Jan;288(1):88-92
references.pmid: 9862757
references.citation: Bioorg Med Chem Lett. 2005 Feb 15;15(4):877-81
references.pmid: 15686879
references.citation: Mol Psychiatry. 2002;7(6):525-35
references.pmid: 12140772
references.citation: J Chem Inf Model. 2010 Jun 28;50(6):1123-33
references.pmid: 20578728
references.citation: Mol Pharmacol. 2008 Jun;73(6):1838-43
references.pmid: 18367540
references.citation: J Med Chem. 2005 Mar 24;48(6):1721-4
references.pmid: 15771418
references.citation: Cell Mol Neurobiol. 2007 Aug;27(5):609-39
references.pmid: 17554626
references.citation: J Pharm Pharmacol. 2006 Mar;58(3):281-93
references.pmid: 16536894
references.citation: Mol Pharmacol. 2003 Dec;64(6):1283-94
references.pmid: 14645658
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):703-11
references.pmid: 19481063